Product Number: S013014
English Name: Silodosin Impurity 14
English Alias: (R)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)-1H-indole-7-carboxamide
CAS Number: None
Molecular Formula: C₂₂H₂₄F₃N₃O₃
Molecular Weight: 435.44
As a chiral impurity of silodosin, the research advantages of this compound lie in:
Analyzing the by-product formation mechanism of amination and etherification reactions during silodosin synthesis to optimize processes for controlling chiral impurity generation;
Serving as a chiral reference standard containing trifluoroethoxy and indole ring structures to provide a standard substance for detecting complex chiral impurities in drugs, improving the accuracy of enantiomer separation and detection;
Helping study the impact of trifluoro substituents and indole ring structures on drug stability and toxicological properties to provide a scientific basis for formulating impurity control strategies.
Drug Development: Used as a chiral impurity reference standard to identify and quantify Impurity 14 in silodosin preparations, evaluating the stereochemical purity of APIs and formulations;
Quality Control: Acting as a standard substance to validate the sensitivity of chiral HPLC or supercritical fluid chromatography (SFC) and other detection methods, ensuring chiral impurity content meets pharmacopoeia requirements during production;
Stability Studies: Simulating ether bond cleavage or amide hydrolysis pathways under drug storage conditions to assist in establishing storage conditions and shelf life.
Silodosin is a highly selective α1A-adrenergic receptor antagonist used for the treatment of benign prostatic hyperplasia. Its molecular structure contains multiple chiral centers and fluorinated functional groups, making it prone to generating stereoisomeric impurities during synthesis. Silodosin Impurity 14, as an indole derivative with (R)-configuration, may be formed during condensation reactions or chiral induction, and its content directly affects drug quality. Since chiral isomers may have different pharmacological activities or toxicities, research on this impurity is a key part of silodosin quality control.
Current research focuses on:
Chiral Synthesis Processes: Developing highly stereoselective impurity synthesis methods to obtain single-configuration reference standards through chiral catalysts or resolution techniques;
Detection Technologies: Establishing high-resolution enantiomer separation and detection methods using chiral stationary phase HPLC or LC-MS combined techniques;
Toxicological Evaluation: Studying the impact of (R)-configuration on potential drug toxicity through in vitro cytotoxicity experiments;
Process Control: Analyzing the influence of parameters such as amination reaction temperature and solvent polarity on stereoselectivity to optimize conditions for reducing chiral impurity generation.
China
